Altimmune (NASDAQ:ALT) Research Coverage Started at Barclays

Barclays began coverage on shares of Altimmune (NASDAQ:ALT) in a research report sent to investors on Tuesday, MarketBeat Ratings reports. The firm issued an overweight rating and a $20.00 price target on the stock.

A number of other equities analysts also recently issued reports on ALT. Citizens Jmp cut their price target on Altimmune from $15.00 to $14.00 and set a “market outperform” rating for the company in a research note on Friday, November 7th. Citigroup reaffirmed a “market outperform” rating on shares of Altimmune in a research report on Wednesday, November 12th. HC Wainwright reiterated a “buy” rating and set a $12.00 price target on shares of Altimmune in a report on Monday, October 20th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Altimmune in a research note on Monday, December 29th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $17.17.

Altimmune Stock Performance

Shares of ALT stock opened at $5.10 on Tuesday. The company has a current ratio of 17.18, a quick ratio of 17.18 and a debt-to-equity ratio of 0.08. The firm has a fifty day simple moving average of $4.65 and a two-hundred day simple moving average of $4.15. Altimmune has a 12 month low of $2.90 and a 12 month high of $7.73. The firm has a market capitalization of $532.13 million, a PE ratio of -4.77 and a beta of 0.04.

Altimmune (NASDAQ:ALT) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.08. The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.00 million. Altimmune had a negative net margin of 419,575.00% and a negative return on equity of 54.79%. Analysts forecast that Altimmune will post -1.35 EPS for the current fiscal year.

Insiders Place Their Bets

In other Altimmune news, Director John Gill purchased 12,500 shares of the company’s stock in a transaction that occurred on Tuesday, December 23rd. The shares were acquired at an average cost of $4.10 per share, for a total transaction of $51,250.00. Following the completion of the acquisition, the director owned 12,500 shares of the company’s stock, valued at $51,250. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jerome Benedict Durso acquired 12,500 shares of the business’s stock in a transaction on Monday, December 22nd. The stock was acquired at an average cost of $4.13 per share, for a total transaction of $51,625.00. Following the transaction, the director owned 12,500 shares of the company’s stock, valued at approximately $51,625. The trade was a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased 30,527 shares of company stock worth $125,278 over the last quarter. 4.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Altimmune

A number of large investors have recently added to or reduced their stakes in ALT. Concurrent Investment Advisors LLC raised its position in Altimmune by 10.4% in the fourth quarter. Concurrent Investment Advisors LLC now owns 26,508 shares of the company’s stock worth $96,000 after acquiring an additional 2,500 shares during the period. Kingswood Wealth Advisors LLC grew its position in shares of Altimmune by 133.8% during the 4th quarter. Kingswood Wealth Advisors LLC now owns 36,000 shares of the company’s stock valued at $130,000 after acquiring an additional 20,600 shares during the period. Summit Financial Wealth Advisors LLC increased its stake in shares of Altimmune by 7.3% during the 4th quarter. Summit Financial Wealth Advisors LLC now owns 103,288 shares of the company’s stock worth $373,000 after purchasing an additional 7,000 shares during the last quarter. Wealth Effects LLC raised its holdings in shares of Altimmune by 86.7% in the 4th quarter. Wealth Effects LLC now owns 111,750 shares of the company’s stock worth $403,000 after purchasing an additional 51,900 shares during the period. Finally, Hennion & Walsh Asset Management Inc. lifted its stake in Altimmune by 15.7% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 214,632 shares of the company’s stock valued at $775,000 after purchasing an additional 29,057 shares during the last quarter. Hedge funds and other institutional investors own 78.05% of the company’s stock.

Key Headlines Impacting Altimmune

Here are the key news stories impacting Altimmune this week:

• Positive Sentiment: Raised capital to fund Phase 3 — Altimmune closed a registered direct offering that raised approximately $75 million to support the upcoming Phase 3 trial for pemvidutide and to bolster working capital, reducing near-term financing risk and extending the company’s runway. Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock
• Positive Sentiment: Bullish analyst initiation — Barclays initiated coverage with an “Overweight” rating and a $20 price target, giving the stock a material upside narrative that can attract institutional interest and support longer-term valuation. ALT-Altimmune initiated with bullish view at Barclays
• Neutral Sentiment: Retail speculation and momentum — Retail-driven buying and buyout rumors have contributed to several days of gains leading into the offering, creating short-term volatility that can amplify moves in either direction. This is speculative and not tied to new fundamental data beyond the offering. ALT stock surges toward sixth straight day of gains
• Negative Sentiment: Dilution and immediate sell pressure — The offering involved ~17.0M shares (or pre-funded warrants), which triggered sell-side coverage and headline-driven selling; outlets noted shares slid on the pricing/announcement, reflecting dilution concerns and a near-term headwind to the share price. Altimmune Shares Slide on $75 Million Pricing of Offering
• Negative Sentiment: Analyst cautions on Breakthrough designation — Commentators argue FDA Breakthrough Therapy designation and positive Phase 2b topline do not guarantee commercial or regulatory success; investors should expect clinical and execution risk through a Phase 3 program. Altimmune: Why Breakthrough Status Isn’t A ‘Buy’ Signal Just Yet

About Altimmune

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.